Results from the 2 largest retrospective series of pPCL patients treated with auto-SCT
| Characteristics of patients . | Drake et al50 . | Mahindra et al86 . |
|---|---|---|
| N | 272 | 97 |
| Age at SCT, y | 56 | 56 |
| SCT received | 1980-2006 | 1995-2006 |
| β2-Microglobulin, median (mg/L) | 6.8 | NA |
| Induction regimen, % | ||
| Thalidomide-based | NA | 25 |
| Bortezomib-based | NA | 5 |
| Lenalidomide-based | NA | 0 |
| Graft type | ||
| BM | 0.8 | NA |
| BM/PBSC | 1.5 | NA |
| PBSC | 97.7 | NA |
| Conditioning regimen, % | ||
| Melphalan alone | NA | 56 |
| Melphalan + TBI ± others | NA | 11 |
| Melphalan-based, no TBI | NA | 24 |
| TBI included | 9.1 | NA |
| No TBI included | 90.9 | NA |
| Second transplant, % | ||
| Auto-auto | NA | 26 |
| Auto-allo | 10.3 | 4 |
| Disease status at transplantation, % | ||
| CR | 25.5 | 20 |
| PR | 58.7 | 56 |
| ≥ PR | 84.2 | 76 |
| Response post-SCT, % | ||
| CR | 41.2 | NA |
| PR | NA | NA |
| ≥ PR | NA | NA |
| PFS at 3 years | 38 | 34% |
| OS at 3 years | 39.5 | 64% |
| NRM at 3 years | NA | 5% |
| Characteristics of patients . | Drake et al50 . | Mahindra et al86 . |
|---|---|---|
| N | 272 | 97 |
| Age at SCT, y | 56 | 56 |
| SCT received | 1980-2006 | 1995-2006 |
| β2-Microglobulin, median (mg/L) | 6.8 | NA |
| Induction regimen, % | ||
| Thalidomide-based | NA | 25 |
| Bortezomib-based | NA | 5 |
| Lenalidomide-based | NA | 0 |
| Graft type | ||
| BM | 0.8 | NA |
| BM/PBSC | 1.5 | NA |
| PBSC | 97.7 | NA |
| Conditioning regimen, % | ||
| Melphalan alone | NA | 56 |
| Melphalan + TBI ± others | NA | 11 |
| Melphalan-based, no TBI | NA | 24 |
| TBI included | 9.1 | NA |
| No TBI included | 90.9 | NA |
| Second transplant, % | ||
| Auto-auto | NA | 26 |
| Auto-allo | 10.3 | 4 |
| Disease status at transplantation, % | ||
| CR | 25.5 | 20 |
| PR | 58.7 | 56 |
| ≥ PR | 84.2 | 76 |
| Response post-SCT, % | ||
| CR | 41.2 | NA |
| PR | NA | NA |
| ≥ PR | NA | NA |
| PFS at 3 years | 38 | 34% |
| OS at 3 years | 39.5 | 64% |
| NRM at 3 years | NA | 5% |
NA indicates not available; PBSC, peripheral blood stem cells; TBI, total body irradiation; and NRM, nonrelapse mortality.